CClinicalTrials.gg
Not yet recruitingNCT06342271Updated Apr 2, 2024

Effects of Nordic Walking and Free Walking on Arm Swing Parameters and Gait in Parkinson's Disease

An interventional study of Nordic walking training and Free Walking training in Parkinson Disease, sponsored by University of Talca. Not yet recruiting. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by University of Talca · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

People with Parkinson's Disease(PD) present a series of alterations such as muscle stiffness and motor slowing, which gradually affect the swinging movement of the arms and legs, altering the ability to walk, increasing the risk of falling, and reducing functionality. This implies a higher energy cost and a greater probability of developing freezing of the gait.

Nordic walking (NW) is a form of physical exercise characterized by the use of walking poles, which could contribute positively to arm swing movement and, thus, gait.

This clinical trial aims to compare Nordic Walking with free walking (FW) protocol training and investigate their effects on arm swing and gait parameters in people with PD.

The study hypothesizes that NW training will reduce asymmetry and increase arm swing amplitudes during gait to a greater extent than FW. Also, improvements in arm swing could positively influence lower limb performance during regular gait, increasing gait speed, stride length, functional mobility, and quality of life.

People with PD will complete 24 supervised NW or FW training sessions for 12 weeks. Both trainings will be identical in volume and intensity, the only difference will be the use of poles in the NW group. Blinded researchers will conduct evaluations at baseline (T0), post-intervention (T1), and in one-month follow-up (T2).

Read the detailed description

Primary aims: To compare the effects of Nordic Walking (NW) with a free walking (FW) protocol training on arm swing in people with Parkinson's disease.

Secondary aims: To compare the effects of NW and FW protocol training on the performance of lower limbs during walking, functional mobility, and quality of life in people with Parkinson's disease.

Methodology Study design: randomized controlled clinical trial, parallel, single-blinded. The participants will be invited through posters disseminating the research. Each interested person will be contacted by telephone and invited to the Human Movement Sciences Laboratory of the University of Talca. After signing informed consent, the baseline evaluations will be carried out. A brief questionnaire containing bio-demographic information and health history will be completed to verify the inclusion and exclusion criteria. To establish the disease's stage, the Hoehn and Yahr scale will be applied. The cognitive status will be assessed with the Montreal Cognitive Assessment (MoCA).

After the baseline evaluation, a number will be assigned a number to each participant, and performed a randomization process into blocks of four participants to assign them to study groups.

Twenty-eight people with PD, stages 1-3 on the Hoehn and Yahr scale, will be randomly assigned to the NW training (n = 14) or FW training group (n = 14), according to a sample size calculation, with a 1:1 allocation ratio, matched by disease stage (stages I, II, and III). The distribution will be blinded to the evaluators and statisticians.

Interventions:

The training will be developed on the athletics track and trails of the University of Talca, Chile. The participants will be trained in groups (NW or FW), for 12 weeks, two times a week on alternate days, completing 24 one-hour sessions. The protocol will be standardized for both groups.

Two physiotherapists, blinded to the study groups, will conduct the evaluations at T0 (baseline assessment), T1 (after 12 weeks of intervention), and T2 (one-month follow-up).

To characterize the sample, we will collect bio-demographic information and health data. To evaluate the progression of motor and non-motor symptoms in PD, the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) will be applied. To safeguard the safety of the participants and prescribe the training individually, vital parameters will be assessed. The anthropometric profile will be established through weight, height, and body mass index. The upper and lower limbs' lengths are also measured (m). To assess walking speed, a 10-meter walk test will be applied, and to assess aerobic capacity, a 6-minute walk test will be carried out.

Two accelerometers placed at the wrist level will acquire the arm swing parameters. Arm swing is defined as a rotational movement of the arm, occurring during walking, and running in bipeds in opposite directions (anterior and posterior). With a validated AS algorithm, the amplitude of the arm swing for both upper limbs will be calculated. The arm swing asymmetry will be determined according to the symmetry index, considering the phases of oscillation detected in both arms simultaneously with an equation. The gait temporal-spatial parameters (gait speed and step length) will be acquired under the same test conditions and simultaneously to obtain the arm swing parameters, using a wireless sensor model G-walk® (BTS, Italy). Functional mobility will be measured through the timed up-and-go test (TUG). The quality of life will be assessed through the Parkinson's Disease Questionnaire (PDQ39).

Adherence will be monitored by recording attendance at training sessions. Fully adherent participants will be considered those who attend more than 80% of sessions. Adverse events will be monitored in each session and reported in the results.

Statistic analysis: Descriptive data analysis will be calculated for all variables in both groups at baseline (T0). The normality distribution will be verified. To investigate differences in arm swing parameters, a repeated measures analysis of variance will be performed. To determine intra- and intergroup differences, a Bonferroni post-hoc test will be applied. To estimate the relationship between kinematic parameters and the asymmetry of arm swing with lower limb parameters, Pearson's correlation coefficient will be used. Subsequently, a multiple regression analysis will be performed. In the case of a non-normal distribution, non-parametric tests will be used. For the treatment of missing data, an imputation method using regression will be used. All results with a p-value lower than 0.05 will be considered statistically significant. Additionally, the size of the effect will be determined by Cohen's test.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson disease
  • Arms swing
  • Gait
  • Gait Disorders, Neurologic
  • Nordic Walking
  • Rehabilitation
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 28 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University of Talca is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of idiopathic PD, confirmed by a neurologist following the criteria of the Parkinson disease Society Brain Bank Criteria
  • Age between 50-80 years
  • Disease stage between I and III according to Hoehn and Yahr (Hoehn and Yahr)
  • To be able to walk without technical aids.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment (score \< 26 in the Montreal Cognitive Assessment MoCA).
  • Surgery lasting less than three months or deep brain stimulation (DBS).
  • Presence of comorbidities that contraindicate moderate to high-intensity physical exercise.
  • Participate in any walking training two or more times per week.
  • Diagnosis of any other neurological or musculoskeletal condition that can cause motor compromise and interfere with locomotion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Nordic Walking group

    The group will be training with a Nordic Walking protocol for 12- weeks, two times a week, completing 24 one-hour sessions.

    Other: Nordic walking training

  • Active comparator
    Free Walking group

    The group will be training with a Free Walking protocol for 12- weeks, two times a week, completing 24 one-hour sessions.

    Other: Free Walking training

Interventions

  • OtherNordic walking training

    Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.

  • OtherFree Walking training

    Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.

06

What researchers measure

Primary outcomes

  1. Change in the amplitude of arm swing

    It is the movement of the arms in the antero-posterior direction during walking. Measurements will be made through accelerometers, and the unit of measurement will be degrees.

    Time frame: Before, after 12-weeks of training, and after one-month of follow-up.

  2. Change in the arm swing asymmetry

    Asymmetry of the amplitude of movement between left and right swings during walking (0% means no asymmetry) \[%\]

    Time frame: Before, after 12-weeks of training, and after one-month of follow-up.

Secondary outcomes

  1. Change in the temporospatial measurements during walking including measurements of Gait speed [m/s] and step length [m].

    will be assessed using wireless IMU sensor model G-walk (BTS, Italy)

    Time frame: Before, after 12-weeks of training, and after one-month of follow-up.

  2. Change in the functional mobility will be measured through the Timed up and go (TUG).

    TUG measures the function of the lower limbs, mobility, and risk of falling. It consists of a measurement of the time taken to complete a circuit of three meters in seconds.

    Time frame: Before, after 12-weeks of training, and after one-month of follow-up.

  3. Change in the quality of life

    Quality of life will be assessed through the Parkinson's Disease Questionnaire (PDQ39)

    Time frame: Before, after 12-weeks and after one-month of follow-up.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342271
Lead sponsor
University of Talca
Responsible party
Jéssica Espinoza Araneda (Professor, University of Talca) — Principal investigator
First posted
Apr 2, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Mar 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Apr 2, 2024

Study contacts

Jessica Espinoza, PT, MsC, PhD
Contact
jeespinoza@utalca.cl
+56991659008
Cristian Caparrós Manosalva, PT, MsC, PhD
Contact
ccaparros@utalca.cl
+56953424032
Jéssica Espinoza, PT, MsC, PhD
principal investigator · University of Talca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion